Side-by-side financials for EDIT and AMGN. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | EDIT | AMGN |
|---|---|---|
| Market cap | - | $191.70 B |
| US-listed rank | - | #79 |
| Revenue (latest FY) | $40.52M | $36.75B |
| Net income (latest FY) | -$160.06M | $7.71B |
| Net margin | -395.0% | 21.0% |
| P/E (trailing FY) | - | 24.9 |
| SEC filings | 693 | 1,011 |
In their latest fiscal years, Editas Medicine, Inc. reported $40.52M in revenue while AMGEN INC reported $36.75B.
Full pages: Editas Medicine, Inc. and AMGEN INC, or browse the full rankings.